ROHTO PHARMACEUTICAL CO.,LTD.
ロート製薬株式会社
Valuation
Fundamental ratios for the latest reported period.
Ticker: 4527
FY2025 (Mar 2026) · J-GAAP · consolidated Source: filing S100YE5N
FY = fiscal year, named by the calendar year it starts in; the month in brackets is when it ends (FY2025 ends Mar 2026 for a March year-end). FY2025 (Mar 2026) runs Apr 1, 2025 – Mar 31, 2026.
| Gross margin | 56.1% |
|---|---|
| Operating margin | 12.0% |
| Net margin | 10.0% |
| Return on equity | 12.1%Includes one-off items (e.g. gains on negative goodwill) |
| Return on assets | 7.4% |
| Revenue growth (YoY) | 11.4% |
| EPS (basic) | ¥151.56 |
| EPS growth (YoY) | 12.0% |
| Current ratio | 2.04x |
| Equity ratio | 62.1% |
| Book value / share | ¥1,334.04 |
| Free cash flow | ¥21.5B |